Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
Pham
S M
SM
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Kormos
R L
RL
Kawai
A
A
Murali
S
S
Hattler
B G
BG
Demetris
A J
AJ
Griffith
B P
BP
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003141:Communicable Diseases / Q000453:epidemiology; D003327:Coronary Disease / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus